No abstract

Idiopathic overactive bladder (OAB) is a chronic condition that negatively affects quality of life, and oral medications are an important component of the OAB treatment algorithm. Recent literature has shown that anticholinergics, the most commonly prescribed oral medication for the treatment of OAB, are associated with cognitive side effects including dementia. β3-adrenoceptor agonists, the only alternative oral treatment for OAB, are similar in efficacy to anticholinergics with a more favorable side effect profile without the same cognitive effects. However, there are marked cost variations and barriers to access for OAB medications, resulting in expensive copays and medication trial requirements that ultimately limit access to β3-adrenoceptor agonists and more advanced procedural therapies. This contributes to and perpetuates health care inequality by burdening the patients with the least resources with a greater risk of dementia. When prescribing these medications, health care professionals are caught in a delicate balancing act between cost and patient safety. Through multilevel collaboration, we can help disrupt health care inequalities and provide better care for patients with OAB.

ObjectivesThe aims of this study were to assess the in vitro biofilm-producing capabilities of uropathogens grown from a postmenopausal urogynecologic population with isolated and recurrent urinary tract infection (UTI) and to determine whether the biofilm-producing bacterial phenotype was associated with recurrent infection.MethodsThis was an institutional review board–approved cross-sectional analysis within a large academic referral center. Uropathogens were cultured from postmenopausal women with either isolated or recurrent acute UTI and then screened for in vitro biofilm formation using crystal violet microtiter assays. Demographic and clinical variables, including pelvic floor symptoms and surgical history were collected and analyzed. A multivariate model was developed to determine whether recurrent UTI was independently associated with biofilm production.ResultsEighty-nine women were included: 67.4% White, 25.8% Black, 3.4% Asian, and 1.1% Hispanic with a mean age of 72 ± 10.5 years. Ninety-five uropathogen strains were isolated. Most uropathogens produced biofilm (n = 53, 55.8%). Uropathogens from women with recurrent UTI were significantly more likely to produce biofilm (70%) than uropathogens collected from women with isolated UTI (38.6%, P = 0.0033). Adjusting for age, prior pelvic reconstructive surgery, and body mass index, recurrent UTI bacteria were more likely to produce biofilm, compared with isolated UTI (odds ratio, 5.37; 95% confidence interval, 2.0–14.4; P = 0.001).ConclusionsIn this cohort of postmenopausal urogynecology patients, in vitro biofilm formation was more frequently observed in uropathogens isolated from women with recurrent UTI compared with women with isolated UTI. Further study is needed to assess the role of biofilms in recurrent UTIs in postmenopausal women.

(Abstracted from Female Pelvic Med Reconstr Surg 2022;28:e127–e132)With 50% to 70% of women reporting a urinary tract infection (UTI) at some point in their lives, the diagnosis and treatment of this condition are common. Recurrent UTI occurs in approximately 20% to 30% of women, and estimated annual total health care costs of UTIs reside around $2.3 billion.

No abstract

OBJECTIVE: As chronic pelvic pain can be a challenge for both patients and their physicians, we present our approach to the management of pelvic floor myofascial spasm and how/when to perform pelvic floor trigger point and botulinum A injections. DESCRIPTION: The video summarizes therapeutic options for pelvic floor myofascial spasm and details the procedure used for officebased pelvic floor trigger point injections and botulinum A injections in the operating room. CONCLUSION: In cases of myofascial pain syndrome, multi-modal therapy including physical therapy, medical management, and trigger point injections is often required.

No abstract

No abstract